Alcohol and Dextrose and Milnacipran
Determining the interaction of Alcohol and Dextrose and Milnacipran and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using milnacipran together with ethanol. Milnacipran may cause liver damage, and taking it with alcohol may increase that risk. You should avoid or limit the use of alcohol while being treated with milnacipran. Call your doctor immediately if you have fever, chills, joint pain or swelling, excessive tiredness or weakness, unusual bleeding or bruising, skin rash or itching, loss of appetite, nausea, vomiting, dark colored urine, or yellowing of the skin or the whites of your eyes, as these may be symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury. Milnacipran alone can increase serum transaminase levels. In placebo-controlled fibromyalgia trials, increases in ALT were more frequently observed in patients treated with milnacipran 100 mg/day (6%) and 200 mg/day (7%) compared to patients treated with placebo (3%). One patient receiving milnacipran 100 mg/day (0.2%) had an increase in ALT greater than 5 times the upper limit of normal (ULN) but did not exceed 10 times the ULN. Increases in AST were also more frequently observed in patients treated with milnacipran 100 mg/day (3%) and 200 mg/day (5%) than in patients treated with placebo (2%). There have been reported cases of increased liver enzymes and severe liver injury, including fulminant hepatitis, from foreign postmarketing experience with milnacipran. Significant underlying clinical conditions and/or use of multiple concomitant medications were present in the cases of severe liver injury.
MANAGEMENT: Due to the risk of liver injury, milnacipran should generally not be prescribed to patients with substantial alcohol use.
- "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.
Generic Name: ethanol
Brand name: Ablysinol
Synonyms: Alcohol, Dehydrated Alcohol Injection
Generic Name: milnacipran
Brand name: Savella, Savella Titration Pack
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alcohol and Dextrose-Milnacipran Hydrochloride
- Alcohol and Dextrose-Milrinone
- Alcohol and Dextrose-Milrinone Dextrose
- Alcohol and Dextrose-Milrinone Injection
- Alcohol and Dextrose-Milrinone Lactate
- Alcohol and Dextrose-Milrinone Lactate in Dextrose Injection
- Milnacipran-Alcohol in Dextrose
- Milnacipran-Alcortin A
- Milnacipran-Alcortin A Gel
- Milnacipran-Alcortin A topical
- Milnacipran-Aldactazide
- Milnacipran-Aldactone